Tylosin A, EvoPure®

Tylosin A, EvoPure®is a highly purified (>99 %) form of Tylosin A. Tylosin is a macrolide antibiotic that was originally isolated from Streptomyces fradiae by the Lilly Research Labs in 1961 from a soil sample collected in Thailand. Tylosin is a mixture of four macrolide antibiotics, the main component of the mixture (> 80%) is tylosin A; tylosin B (desmycosin), tylosin C (macrocin), and tylosin D (relomycin) may also be present. Tylosin has broad-spectrum bacteriostatic activity against Gram-positive bacteria and mycoplasma, but much less activity against most Gram-negative bacteria and fungi.
Tylosin A contains a polyketide lactone (tylactone) substituted with three 6-deoxyhexose sugars. The addition of D-mycaminose to the aglycone is followed by concurrent ring oxidation at C-20 and C-23 (to generate the tylonolide moiety) and substitution with L-mycarose and 6-deoxy-Dallose.
Tylosin, like other Macrolide antibiotics, is a bacteriostatic compound that reversibly bind to the 23S rRNA in the 50S (L27 protein) ribosome subunit and inhibit mRNA-directed protein synthesis.
Tylosin has been used to study protein synthesis, abscess prevention in cattle, and Mycoplasma infections.

Please contact us at for specific academic pricing.

Background

Tylosin A binds to the 50S ribosomal subunit interfering with the binding of aminoacyl-tRNA-to 50S and block peptide bond formation. This inhibits the translocation of a newly synthesized peptidyl tRNA molecule from the acceptor site to the peptidyl site.